USA flag logo/image

An Official Website of the United States Government

Identification of Novel Influenza Inhibitors

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88774
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
AI079856
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
INTEGRAL MOLECULAR
3711 MARKET ST Suite 900 PHILADELPHIA, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Identification of Novel Influenza Inhibitors
Agency: HHS
Contract: 1R43AI079856-01
Award Amount: $599,243.00
 

Abstract:

DESCRIPTION (provided by applicant): Influenza virus is a Category C biodefense pathogen of global public health concern because it causes 3-5 million cases of severe illness every year, and because of the potential for the emergence of new, highly pathoge nic strains that could cause pandemic disease. To date, there have been only two successfully-exploited influenza drug targets and only four approved drugs. The M2 H+ ion channel has been shown to be necessary for viral infectivity, and suppression of its activity is a well validated anti-viral strategy. The compounds amantadine and rimantadine inhibit M2 and have been used as influenza therapeutics for the past 40 years. However, many currently circulating influenza strains now exhibit resistance to them. New drugs that inhibit M2 via novel mechanisms of interaction therefore have significant potential as influenza therapeutics. However, conventional methods for studying the activity of ion channels are poorly suited to high-throughput screening techniques for identifying new inhibitors. Until now, this has largely precluded the development of new classes of M2 inhibitors. Integral Molecular specializes in developing novel strategies for manipulating and studying integral membrane proteins, including ion cha nnels. We have developed a novel technology for monitoring the activity of M2 that we have shown to be well-suited to high-throughput screening (HTS) applications. Having successfully developed a suitable HTS assay for M2 screening, the current application proposes to use it to identify and develop novel M2 inhibitors. PUBLIC HEALTH RELEVANCE: The product that will result from this SBIR is a novel small molecule inhibitor of influenza. The inhibitors developed in this proposal will target a validated influe nza molecular target, M2, and overcome the major obstacles faced by the adamantane drugs because compounds will be screened for potency against a number of M2 variants to maximize the chances of developing a broad-spectrum influenza inhibitor. M2 is critic al to the influenza life-cycle, suggesting there is substantial therapeutic potential for next-generation inhibitors of M2 activity.

Principal Investigator:

Benjamin J. Doranz
2159666018
BDORANZ@INTEGRALMOLECULAR.COM

Business Contact:


bdoranz@integralmolecular.com
Small Business Information at Submission:

INTEGRAL MOLECULAR
INTEGRAL MOLECULAR 3701 MARKET ST, STE 340 PHILADELPHIA, PA 19104

EIN/Tax ID: 233091965
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No